Stockreport

Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting [Yahoo! Finance]

BioNTech SE - American Depositary Shares  (BNTX) 
PDF Ryvu's WRN inhibitor program has demonstrated target engagement and selective potency with a synthetic lethal effect; in vivo efficacy studies exhibited pronounced tumo [Read more]